BNC210

BNC210 (H-Ile-Trp-OH) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. BNC210 exhibits acute anxiolytic activity in rodent models of anxiety. BNC210 inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 with IC50 values in the range of 1.2 to 3 μM. BNC210 can be used in studies of anxiety, trauma, and stressor-related disorders[1][2][3][4].

[1]Wise T, et al. Cholinergic modulation of disorder-relevant neural circuits in generalized anxiety disorder. Biological psychiatry, 2020, 87(10): 908-915. |[2]Hampsey E, et al. BNC210: an investigational α7-nicotinic acetylcholine receptor modulator for the treatment of anxiety disorders. Expert Opin Investig Drugs. 2023 Apr;32(4):277-282.|[3]O'Connor SM, et al. BNC210, a negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor, demonstrates anxiolytic- and antidepressant-like effects in rodents. Neuropharmacology. 2024 Mar 15;246:109836.|[4]Andriambeloson E, et al. BNC210: A Novel Compound with Potent Anxiolytic Activity[C]//BEHAVIOURAL PHARMACOLOGY. 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA: LIPPINCOTT WILLIAMS & WILKINS, 2007, 18: S16-S16.